Sign in

You're signed outSign in or to get full access.

Deborah Kaster

Chief Financial Officer and Chief Business Officer at Adagio Medical Holdings
Executive

About Deborah Kaster

Deborah Kaster, 55, is Adagio Medical Holdings’ Chief Financial Officer and Chief Business Officer; she became CBO in April 2025 and added CFO, principal financial officer, and principal accounting officer responsibilities effective September 5, 2025 . She holds a B.A. in Economics from Cornell University and an M.B.A. in Finance and Strategy from The Wharton School; prior roles include VP of Investor Relations at Shockwave Medical and Managing Director at Gilmartin Group, with earlier experience in business development at Kyphon and medical device investment banking at Piper Jaffray/U.S. Bancorp . The company has not disclosed TSR, revenue growth, or EBITDA growth metrics tied specifically to her performance for 2025 to date .

Past Roles

OrganizationRoleYearsStrategic Impact
Shockwave Medical, Inc.Vice President, Investor Relations2020–2024Led IR program; supported corporate strategy, financial forecasting, and investor/analyst communications
Gilmartin Group LLCManaging Director2015–2020Advised medtech companies on strategy and capital markets communications
Kyphon, Inc.Business Development leaderNot disclosedRan BD at a public medtech company (transactional and strategic partnerships)
Piper Jaffray/U.S. Bancorp Piper JaffrayInvestment Banker, MedtechNot disclosedCovered medical device sector M&A/financings

External Roles

OrganizationRoleYearsNotes
No public company directorships or external board roles disclosed

Fixed Compensation

ComponentTermsEffective Date/Status
Base Salary$366,000 annual base salary Effective Sept 5, 2025
Contingent Salary IncreaseEligible for at least a 4% increase upon closing of a Board-approved equity financing raising ≥$5 million; such financing occurred in October 2025 Trigger satisfied Oct 2025 (exact new salary not disclosed)
BenefitsStandard executive-level benefits Ongoing

Performance Compensation

Incentive TypeTarget/OpportunityMetrics/DeterminationPayout MechanicsVesting
Annual Performance and Retention Bonus (cash)Up to 40% of base salary Discretionary; specific quantitative metrics not disclosed Annual cash bonus; prorated upon certain terminations (see Employment Terms) N/A
Stock Options (Time-based)728,000 options out of 819,000 total grant (April 2025) Time-based only N/A25% (182,000 options) vests on April 1, 2026; remaining 75% vests in 36 equal monthly installments thereafter, subject to continued employment
Stock Options (Change-in-Control tranche)91,000 options out of 819,000 total grant (April 2025) CoC-based (consideration > $250,000,000) N/AVests immediately upon consummation of a qualifying Change in Control, subject to continued employment through closing

Equity Ownership & Alignment

ItemDetail
Beneficial Ownership (as of Oct 24, 2025)0 shares of common stock; <1% ownership
Options/RSUs exercisable/vestable within 60 days (as of Oct 24, 2025)0 (initial cliff for time-based options is April 1, 2026)
Unvested Equity (indicative)728,000 time-based options unvested; 91,000 CoC-based options contingent on qualifying CoC
Pledging/HedgingProhibited: no pledging, hedging, short sales, or margin accounts permitted for insiders
Insider Trading ControlsBlackouts around quarters; mandatory pre-clearance; 10b5-1 plans permitted with cooling-off periods
Stock Ownership GuidelinesCompensation Committee monitors any guidelines; specific executive multiples not disclosed

Employment Terms

TermDetail
RolesChief Business Officer since April 2025; Chief Financial Officer and principal financial/accounting officer effective Sept 5, 2025
Employment StatusAt-will employment
Severance (Non-CoC Qualifying Termination)6 months base salary continuation plus prorated bonus opportunity, subject to release
Severance (CoC Double-Trigger Window)If termination without Cause or for Good Reason occurs from 3 months before to 12 months after a CoC: 12 months base salary plus lump sum equal to target annual bonus (prorated), subject to release
CoC Equity AccelerationSeparate 91,000-option tranche vests immediately upon qualifying CoC with total stockholder consideration > $250,000,000 (single-trigger for that tranche), subject to continued employment through closing
ClawbackCompany-wide clawback policy compliant with Rule 10D-1; recovers excess incentive comp over prior 3 completed fiscal years following a restatement

Compensation Structure Analysis

  • Mix and risk: 2025 package emphasizes at-risk pay via sizable option grant (819,000 options), with the majority time-based over four years, aligning retention; cash bonus is discretionary up to 40% of salary, with no preset metric disclosure, which increases committee discretion .
  • Vesting-driven selling pressure: First vesting event on April 1, 2026 (25% of the 728,000 time-based option tranche) could create an initial liquidity event; thereafter, monthly vesting may smooth supply .
  • CoC incentives: Immediate vesting of a 91,000-option tranche upon a sale exceeding $250M consideration creates a potential alignment with value-creating strategic outcomes, while severance is double-triggered in the CoC window (12 months salary plus prorated target bonus) .
  • Governance guardrails: Company prohibits pledging and hedging and maintains a 10D-compliant clawback, mitigating misalignment and misconduct risk .

Performance & Track Record

  • Company commentary highlights Ms. Kaster’s immediate impact in driving strategic initiatives and partnerships since joining in 2025, and the company executed an equity financing in October 2025 that triggered her salary step-up provision (≥4%) .
  • No TSR, revenue growth, or EBITDA growth performance metrics have been disclosed that are specifically tied to her 2025 incentive outcomes .

Investment Implications

  • Alignment and retention: Near-zero current share ownership but substantial unvested, time-based options with a 2026 cliff and monthly vesting thereafter signal strong retention hooks and limit near-term selling pressure; prohibited pledging/hedging further aligns interests .
  • Deal optionality: A discrete 91,000-option tranche accelerates on a >$250M CoC, offering upside leverage to strategic outcomes while severance remains double-triggered, balancing alignment with shareholder value creation against windfall risk .
  • Pay-for-performance: Bonus is discretionary up to 40% of salary without disclosed quantitative targets, increasing committee flexibility but reducing transparency; the company’s clawback policy provides a backstop on incentive integrity .
  • Near-term catalysts: The initial option cliff on April 1, 2026, and ongoing monthly vesting are the primary dates to monitor for potential insider selling activity, subject to trading windows and pre-clearance/10b5-1 plans .